We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery No Help for Mild Knee Osteoarthritis

By HospiMedica International staff writers
Posted on 10 Sep 2014
Arthroscopic surgery for degenerative meniscal tears in patients with mild knee osteoarthritis (OA) had no benefit for function or pain, according to a new study.

Researchers at McMaster University (Hamilton, ON, Canada) searched MEDLINE, Embase, and the Cochrane databases for randomized controlled trials (RCTs) published from 1946 to 2014. More...
Two reviewers independently screened all titles and abstracts for eligibility, and assessed risk of bias for all included studies and pooled outcomes using a random-effects model. In all, seven RCTs involving 805 patients were included in the review.

The results showed that the pooled treatment effect of arthroscopic surgery did not show a significant or minimally important difference (MID) between treatment arms for long-term functional outcomes. Short-term functional outcomes between groups were significant, but did not exceed the threshold for MID. The researchers also found that arthroscopic surgery did not result in a significant improvement in pain scores in the short term or in the long term. The study was published on August 25, 2014, in CMAJ.

“Arthroscopic debridement or washout of knee osteoarthritis has come under lots of scrutiny, based upon trials that suggest patients get no benefit from the procedure. We're concerned that many surgeons worldwide may still be doing this procedure,” said senior author Mohit Bhandari, MD, PhD. “In the context of limited healthcare resources, clinicians must carefully select patients with degenerative meniscal pathology who would benefit from surgical intervention. The results of this meta-analysis suggest that an initial trial of non-operative interventions should play a large role for middle-aged patients.”

OA is a group of mechanical abnormalities involving degradation of joints, including the articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety of causes—hereditary, developmental, metabolic, and mechanical deficits—may initiate processes leading to loss of cartilage. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may become more lax. OA of the knee affects approximately 250 million people worldwide (3.6% of the population).

MID is defined as the smallest effect that an informed patient would perceive as valuable enough to justify a change in therapeutic management, when weighing the anticipated benefits against the possible harms of an intervention.

Related Links:

McMaster University



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.